News

Patented Medicine Prices Review Board explores possible changes to how it conducts business

December 11, 2017

The Patented Medicine Prices Review Board (PMPRB) today published a scoping paper which provides its initial thoughts on how best to operationalize the Minister of Health’s proposed amendments to the Patented Medicines Regulations, which were published in the Canada Gazette, Part I on December 2, 2017.


Federal Minister of Health tables the 2016 Annual Report of the Patented Medicine Prices Review Board

October 27, 2017

The Honourable Ginette Petitpas Taylor, Federal Minister of Health, yesterday tabled the 2016 Annual Report of the Patented Medicine Prices Review Board (PMPRB) with the Clerks of the House of Commons and the Senate.


Study finds significant overlap in the drugs covered by Canadian public drug plans

October 11, 2017

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System research initiative, today published Alignment Among Public Formularies in Canada - Part 1: General Overview.


PMPRB Hearing Panel issues decision in Soliris case

September 27, 2017

A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc.


After several years of low growth, public drug plan expenditures up sharply in 2015-16

May 24, 2017

$1 billion increase from 2014-15 fueled largely by new, higher-cost drugs


PAGE 1 - 2 - 3 - 4 - 5  NEXT 25  LAST 5 
Date modified: